5-Amino-1MQ: Compound Profile

Unlike most compounds Nexara tracks, 5-Amino-1MQ is not a peptide at all but a small quaternary heterocycle, and it earns its place in the metabolic-research literature by acting on a single enzyme rather than a receptor. This profile covers what it is, the NNMT-inhibition mechanism the research attributes to it, and where it sits among the metabolic research compounds. For the wider class context, see the metabolic peptides overview.

What is 5-Amino-1MQ?#

5-Amino-1MQ is a small-molecule research compound, systematic name 1-methylquinolin-1-ium-5-amine, built on a methylquinolinium scaffold that carries a permanent positive charge on its methylated ring nitrogen and a free amine at the 5-position. That quaternary cation is what the chemistry databases register, and it is why the material is usually supplied as a salt. The compound is one of the more frequently referenced small-molecule inhibitors of nicotinamide N-methyltransferase (NNMT), the enzyme it is designed to occupy. The reliable identity anchor here is the chemical record itself together with its enzyme target, rather than any single reported potency figure, which varies by assay format across the literature.

What does the research literature study?#

The compound is studied almost entirely through its target enzyme. NNMT transfers a methyl group from S-adenosylmethionine (SAM) onto nicotinamide, a reaction that draws down two of the cell's central metabolic currencies at once: the methyl-donor pool and the nicotinamide that feeds NAD+ salvage. The foundational small-molecule inhibitor report characterized selective, membrane-permeable NNMT inhibitors in this chemical series and traced their action to that methylation reaction in cell and rodent models. Subsequent work formalized NNMT as a metabolic-syndrome research target and cataloged its role across obesity and glucose-handling models, each framing the enzyme as a control point on the SAM/NAD+ axis. A dietary-plus-inhibition study in mice used NNMT inhibition to probe downstream microbiome shifts, and a separate aged-muscle study examined NNMT inhibition against markers of muscle function in animals. All of this is preclinical enzyme- and pathway-level research; none of it speaks to effects in people.

Because NNMT expression is elevated in several tumor types, the enzyme also appears in the oncology-adjacent literature as a biomarker and target for cancer research and within broader surveys of NAD+ metabolism in disease models. Across these threads, 5-Amino-1MQ functions as a tool compound: a way to switch the enzyme off in a controlled model and observe how methylation flux and NAD+ salvage respond.

Where 5-Amino-1MQ sits among metabolic research compounds#

Most of Nexara's metabolic-class entries are peptides that engage cell-surface receptors. 5-Amino-1MQ is the outlier: a small molecule that works inside the cell on an enzyme, making it a mechanistic contrast rather than a peer of the incretin and amylin peptides. That places it closer, conceptually, to other intracellular-metabolism tool compounds Nexara stocks than to the receptor agonists. The catalog holds it as 5-Amino-1MQ for laboratory research; researchers assembling metabolic-pathway panels often study it alongside the receptor-level peptides covered in the metabolic peptides overview to separate enzyme-level from receptor-level effects.

Handling and storage#

5-Amino-1MQ is supplied as a lyophilized powder and dissolved prior to use. As a small charged molecule rather than a peptide, it still follows the catalog's handling conventions: the reconstitution primer covers solvent selection and getting clean solution, while the cold-chain article covers how storage stability changes once the powder is in solution. Sealed lyophilized material is typically held cold and protected from light and moisture, with repeated freeze-thaw cycles avoided.

Sources and further reading#

• Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase (PMID 29155147): the primary characterization of the NNMT-inhibitor chemical series relevant to 5-Amino-1MQ. Biochemical Pharmacology 2018.
• Nicotinamide N-methyltransferase (NNMT): a novel therapeutic target for metabolic syndrome (PMID 38919254): a review framing NNMT as a control point on the SAM/NAD+ axis in metabolic research. Frontiers in Pharmacology 2024.
• Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes (PMID 34368359): a survey of NNMT across metabolic model systems. BioMed Research International 2021.
• Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice (PMID 35013352): a preclinical study using NNMT inhibition to probe downstream shifts. Scientific Reports 2022.
• NNMT inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice (PMID 38969654): an aged-animal study of NNMT inhibition and muscle-function markers. Scientific Reports 2024.
• Nicotinamide N-Methyltransferase: A Promising Biomarker and Target for Human Cancer Therapy (PMID 35756670): NNMT as a biomarker and target in oncology research. Frontiers in Oncology 2022.
• 5-Amino-1MQ, PubChem CID 950107: chemical identity record for the methylquinolinium cation (formula and structure).
• Nicotinamide N-methyltransferase, UniProt P40261: canonical annotation for the enzyme target NNMT.